A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06733935

Title field or adapter rule

{'original_value': 'A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:33.905341+00:00

Published At

2026-10-30T00:00:00+00:00

Record Updated At

2026-10-30

Source Retrieved At

2026-10-31T22:18:41.628690+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Systemic Sclerosis", "Idiopathic Inflammatory Myopathies", "Antineutrophil Cytoplasmic Antibody-Associated Vasculitis", "Rheumatoid Arthritis"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-30", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06733935"

protocolSection.identificationModule.officialTitle

"A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Systemic Sclerosis (protocolSection.conditionsModule.conditions)
• Idiopathic Inflammatory Myopathies (protocolSection.conditionsModule.conditions)
• Antineutrophil Cytoplasmic Antibody-Associated Vasculitis (protocolSection.conditionsModule.conditions)
• Rheumatoid Arthritis (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['NKX019 - CAR NK cell therapy'], 'description': 'NKX019 is an investigational allogeneic CD19-Directed CAR NK', 'name': 'NKX019', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['NKX019 - CAR NK cell therapy'], 'description': 'Lymphodepletion', 'name': 'Fludarabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['NKX019 - CAR NK cell therapy'], 'description': 'Lymphodepletion', 'name': 'Cyclophosphamide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• NKX019 (protocolSection.armsInterventionsModule.interventions[].name)
• Fludarabine (protocolSection.armsInterventionsModule.interventions[].name)
• Cyclophosphamide (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.